Cigna Stock CI
The Cigna Group is a global health services organization that operates through two principal segments. Cigna stock (CI): Quarterly and annual results since 2023 from Quarterly Report and SEC filings: revenue, earnings, balance sheet, cash flow and management guidance, every figure with its source. As of 07/2026, quarterly reporting. Stock analysis by NadirAlpha. Cigna stock (CI): listed on NYSE, WKN A2PA9L. NadirAlpha has evaluated 45 original documents, cross-checked every figure automatically and linked each to its source; sources as of 07/2026. Revenue Q2 2026: USD 71.7 billion (+7% year on year). Latest reported (Q2 2026): Total Pharmacy Customers, Total Medical Customers, Total Customer Relationships. Latest reading: Revenue accelerating, Guidance raised, Strategic pivot.
AI-generated report · not investment advice · figures extracted automatically; please verify against the linked original more
Cigna Current Status
The current state of Cigna at a glance, figures as of Q2 2026, with core figures and the key management statements from the latest filing. NadirAlpha methodology
Assessment by NadirAlpha, as of Q2 2026.
“Our purpose is to improve the lives of each and every customer and patient we serve. By harnessing technology, data and AI to deliver more personalized experiences, improve access and lower costs, we are creating greater value every day. Our strong second quarter results reflect continued progress against these priorities and demonstrate the effectiveness of our strategy and execution.”
Cigna Stock: Key Figures ($ million)
Revenue, margin, earnings and EPS of Cigna per fiscal year, half-year and quarter in $ million, as of Q2 2026, as reported in the filing; restatements show the most recent filing version. NadirAlpha extracts all values automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original. NadirAlpha methodology
All figures serve only to support your own investment decision and are not a recommendation; the company's original reports are authoritative.
Fiscal years
| Period | Revenue | Op. income | Op. income (adj.) | Net income | EPS ($) | OCF | Source |
|---|---|---|---|---|---|---|---|
| FY2025 | 274,900 | 9,200 | 1,700.28 | 5,957 | 22.18 | 9,601 | 26 |
| FY2024 | 247,121 | 9,417 | 7,741 | 3,434 | 12.12 | 10,363 | 18 |
| FY2023 | 195,265 | 8,536 | 7,448 | 5,164 | 17.39 | 11,813 | 10 |
Quarters
| Period | Published | Revenue | Op. income | Op. income (adj.) | Net income | EPS ($) | Cash | Net Debt | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2026-Q2* | 2026-07-30 | 71,668 | 2,676 | 7.78 | 1,660 | 6.29 | 6,298 | 25,580 | 29 |
| 2026-Q1* | 2026-04-30 | 68,494 | 2,358 | 2,058 | 1,654 | 6.26 | 7,040 | 23,860 | 27 |
| 2025-Q4* | 2026-02-05 | 72,472 | 2,345 | 8.08 | 1,234 | 4.59*≈ | 7,676 | 23,787 | 25 |
| 2025-Q3* | 2025-10-30 | 69,748 | 2,578 | 2,096° | 1,868 | 6.98 | 6,025 | 28,015 | 23 |
| 2025-Q2* | 2025-07-31 | 67,178 | 2,306 | 7.2 | 1,532 | 5.71 | 4,329 | 26,439 | 21 |
| 2025-Q1* | 2025-05-02 | 65,502 | 1,971 | -411 | 1,323 | 4.85 | 8,334 | 22,114 | 19 |
| 2024-Q4* | 2025-01-30 | 65,649 | 2,173 | 1,845 | 1,424 | 5.03*≈ | 7,550 | 24,422 | 17 |
| 2024-Q3* | 2024-10-31 | 63,694 | 2,576 | 2,112 | 739 | 2.63 | 5,888 | 26,914 | 15 |
| 2024-Q2* | 2024-08-01 | 60,523 | 2,412 | 1,909 | 1,548 | 5.45 | 6,788 | 25,104 | 13 |
| 2024-Q1* | 2024-05-02 | 57,255 | 2,256 | 6.47 | -277 | -0.97 | 8,439 | 24,329 | 11 |
| 2023-Q4* | 2024-02-02 | 51,114 | 2,060 | 7,429.7 | 1,029 | 3.47*≈ | 7,822 | 23,108 | 9 |
| 2023-Q3* | 2023-11-02 | 49,048 | 2,240 | 2,000 | 1,408 | 4.74 | 8,497 | 22,643 | 7 |
| 2023-Q2* | 2023-08-03 | 48,586 | 2,221 | 1,820 | 1,460 | 4.92 | 9,585 | 23,148 | 5 |
| 2023-Q1* | 2023-05-05 | 46,517 | 2,015 | 1,115 | 1,267 | 4.24 | 7,935 | 24,607 | 3 |
Cigna Balance Sheet & Cash Flow ($ million)
NadirAlpha places cash, debt, operating cash flow and investments of Cigna side by side per period, balance sheet values as of the period end, flow items for the period. NadirAlpha extracts all values automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original. NadirAlpha methodology
Fiscal years
| Period | Published | Cash | Debt | Net Debt | D&A | OCF | Source |
|---|---|---|---|---|---|---|---|
| FY2025 | 2026-02-26 | 7,676 | 31,463 | 23,787 | 2,775 | 9,601 | 26 |
| FY2024 | 2025-01-30 | 7,550 | 31,972 | 24,422 | 2,775 | 10,363 | 17 |
| FY2023 | 2024-02-29 | 7,822 | 30,930 | 23,108 | 3,035 | 11,813 | 10 |
Quarters
| Period | Published | Cash | Debt | Net Debt | D&A | OCF | Source |
|---|---|---|---|---|---|---|---|
| 2026-Q2 | 2026-07-30 | 6,298 | 31,878 | 25,580 | 655 | -421 | 29 |
| 2026-Q1 | 2026-04-30 | 7,040 | 30,900 | 23,860 | 650 | 1,131 | 27 |
| 2025-Q4 | 2026-02-05 | 7,676 | 31,463 | 23,787 | 722 | 6,149 | 25 |
| 2025-Q3 | 2025-10-30 | 6,025 | 34,040 | 28,015 | 697 | 3,418 | 23 |
| 2025-Q2 | 2025-07-31 | 4,329 | 30,768 | 26,439 | 682 | -1,886 | 21 |
| 2025-Q1 | 2025-05-02 | 8,334 | 30,448 | 22,114 | 674 | 1,920 | 19 |
| 2024-Q4 | 2025-01-30 | 7,550 | 31,972 | 24,422 | 646 | 5,212 | 17 |
| 2024-Q3 | 2024-10-31 | 5,888 | 32,802 | 26,914 | 650 | 46 | 15 |
| 2024-Q2 | 2024-08-01 | 6,788 | 31,892 | 25,104 | 738 | 265 | 13 |
| 2024-Q1 | 2024-05-02 | 8,439 | 32,768 | 24,329 | 741 | 4,840 | 11 |
| 2023-Q4 | 2024-02-29 | 7,822 | 30,930 | 23,108 | 765 | 1,467 | 10 |
| 2023-Q3 | 2023-11-02 | 8,497 | 31,140 | 22,643 | 766 | 2,826 | 7 |
| 2023-Q2 | 2023-08-03 | 9,585 | 32,733 | 23,148 | 755 | 2,492 | 5 |
| 2023-Q1 | 2023-05-05 | 7,935 | 32,542 | 24,607 | 749 | 5,028 | 3 |
Cigna Guidance Tracking (latest per metric/period · 25/50)
NadirAlpha records 50 guidance statements of Cigna neutrally: annual and quarterly targets, direction of change and outcome as a dot with legend, with no estimate of our own. NadirAlpha methodology
Direction: confirmedinitiatedraised Verdict: pending
| For period | Guided on | Metric | Guided | Verdict | Direction | Source |
|---|---|---|---|---|---|---|
| FY2026 | 2026-07-30 | EPS (non-GAAP) | 30.45 | 30 | ||
| FY2026 | 2026-04-30 | Cigna Healthcare Adjusted Income from Operations, Pre-Tax | 4,525 | 28 | ||
| FY2026 | 2026-02-05 | Tax rate | ~19% | 25 | ||
| FY2026 | 2026-02-05 | Capex | ~1,300 | 25 | ||
| FY2026 | 2026-02-05 | Evernorth Adjusted Income from Operations, Pre-Tax | 6,900 | 28 | ||
| FY2026 | 2026-02-05 | Cigna Healthcare Medical Care Ratio | 83.7–84.7% | 28 | ||
| FY2026 | 2026-02-05 | Adjusted Income from Operations | 7,950 | 25 | ||
| FY2026 | 2026-02-05 | Adjusted Revenues | ~280,000 | 25 | ||
| FY2026 | 2026-02-05 | Adjusted SG&A Expense Ratio | ~5% | 25 | ||
| FY2026 | 2026-02-05 | Cash Flow from Operations | ~9,000 | 25 | ||
| FY2026 | 2026-02-05 | Shareholder Dividends | ~1,600 | 25 | ||
| FY2026 | 2026-02-05 | Total Medical Customers | ~18.1 | 25 | ||
| FY2025 | 2025-05-02 | EPS (non-GAAP) | 29.6 | – | 24 | |
| FY2025 | 2025-05-02 | Evernorth Adjusted Income from Operations, Pre-Tax | 7,200 | – | 22 | |
| FY2025 | 2025-05-02 | Cigna Healthcare Adjusted Income from Operations, Pre-Tax | 4,125 | – | 22 | |
| FY2025 | 2025-05-02 | Cigna Healthcare Medical Care Ratio | 83.2–84.2% | – | 22 | |
| 2025-Q4 | 2025-01-30 | Tax rate | ~19% | – | 17 | |
| 2025-Q4 | 2025-01-30 | Capex | ~1,400 | – | 17 | |
| 2025-Q4 | 2025-01-30 | Adjusted Income from Operations | 7,900 | – | 17 | |
| 2025-Q4 | 2025-01-30 | Adjusted Revenues | 252,000 | – | 17 | |
| 2025-Q4 | 2025-01-30 | Adjusted SG&A Expense Ratio | ~5.4% | – | 17 | |
| 2025-Q4 | 2025-01-30 | Cash Flow from Operations | ~10,000 | – | 17 | |
| 2025-Q4 | 2025-01-30 | Shareholder Dividends | ~1,600 | – | 17 | |
| 2025-Q4 | 2025-01-30 | Weighted Average Shares Outstanding | 266–270 | – | 17 | |
| 2025-Q4 | 2025-01-30 | Total Medical Customers | ~18.1 | – | 17 | |
| FY2024 | 2024-10-31 | Cigna Healthcare Adjusted Income from Operations, Pre-Tax | 4,775 | – | 16 | |
| FY2024 | 2024-05-02 | EPS (non-GAAP) | 28.4 | – | 16 | |
| FY2024 | 2024-05-02 | Adjusted Income from Operations | 8,065 | – | 12 | |
| FY2024 | 2024-05-02 | Adjusted Income from Operations, Pre-Tax (Evernorth) | 7,000 | – | 12 | |
| FY2024 | 2024-05-02 | Adjusted Income from Operations, Pre-Tax (Cigna Healthcare) | 4,775 | – | 12 | |
| FY2024 | 2024-05-02 | Medical Care Ratio | 81.7–82.5% | – | 12 | |
| FY2024 | 2024-02-02 | Tax rate | 20.5–21% | – | 12 | |
| FY2024 | 2024-02-02 | Capex | ~1,500 | – | 9 | |
| FY2024 | 2024-02-02 | Evernorth Adjusted Income from Operations, Pre-Tax | 7,000 | – | 16 | |
| FY2024 | 2024-02-02 | Cigna Healthcare Medical Care Ratio | 81.7–82.5% | – | 16 | |
| FY2024 | 2024-02-02 | Adjusted Revenues | 235,000 | – | 12 | |
| FY2024 | 2024-02-02 | Adjusted SG&A Expense Ratio | ~6.1% | – | 12 | |
| FY2024 | 2024-02-02 | Cash Flow from Operations | 11,000 | – | 12 | |
| FY2024 | 2024-02-02 | Weighted Average Shares Outstanding | 282–286 | – | 12 | |
| FY2024 | 2024-02-02 | Total Medical Customers | ~19.3 | – | 12 | |
| FY2024 | 2024-02-02 | Shareholder Dividends | ~1,550 | – | 9 | |
| FY2023 | 2023-11-02 | Adjusted Revenues | 192,000 | – | 8 | |
| FY2023 | 2023-11-02 | Cash Flow from Operations | 10,500 | – | 8 | |
| FY2023 | 2023-11-02 | Medical Care Ratio | 81.5–82% | – | 8 | |
| FY2023 | 2023-11-02 | Total Medical Customer Growth | 1,600,000 | – | 8 | |
| FY2023 | 2023-05-05 | EPS (non-GAAP) | 24.75 | – | 8 | |
| FY2023 | 2023-05-05 | Adjusted Income from Operations | 7,360 | – | 6 | |
| FY2023 | 2023-05-05 | Adjusted Income from Operations, Pre-Tax | 6,400 | – | 8 | |
| FY2023 | 2023-02-03 | Tax rate | 21–21.5% | – | 1 | |
| FY2023 | 2023-02-03 | Adjusted SG&A Expense Ratio | ~7.3% | – | 1 |
Cigna Stock: Price & Chart
Interactive price chart of Cigna stock (TradingView) and the trend of key figures from the core tables; the chart loads only after a click and then connects to TradingView. NadirAlpha methodology
Daily candles with news and earnings markers. Loads only on click.
Cigna Event Timeline
What happened at Cigna since 2023: events from the filings, grouped by quarter, with the source date and a clickable source number. NadirAlpha methodology
2026 · 6 events
Total revenues increased 7% to USD 71,668 million, driven by growth in both Evernorth Health Services and Cigna Healthcare 30
2026 outlook for adjusted income from operations raised to at least $30.45 per share 30
Cigna announced planned exit from the Individual and Family Plans medical business as of January 1, 2027 29
“We continue to improve how people experience health care, leveraging innovation and technology to make it more personalized, more transparent and easier to navigate. Our strong first quarter results were driven by disciplined execution, deliberate portfolio shaping and a continued focus on targeted innovation.”
Total revenues increased 5% to USD 68,494 million, driven by Evernorth Health Services, partially offset by lower premiums following the HCSC transaction 28
Cigna Healthcare medical care ratio decreased 240 basis points to 79.8%, primarily due to the HCSC transaction (divestiture of Medicare Advantage businesses, March 2025) 27
2026 outlook for adjusted income from operations per share raised by $0.10 to at least $30.35 per share 28
2025 · 15 events
“In 2025, we expanded access and support, lowered costs, and improved transparency for our customers and patients. As we enter the new year, we are well-positioned to build on this momentum, fueled by our innovations that leverage our diversified businesses and track record of strong financial performance.”
Full-year adjusted income from operations increased 4% to $8.0 billion ($29.84 per share) from $7.7 billion ($27.33 per share) in 2024 25
Cigna Healthcare full-year MCR was 84.4% compared to 83.2% in 2024, primarily due to higher medical costs driven by the Individual and Family Plans business 25
2026 outlook established with adjusted income from operations of at least $7.950 billion, or at least $30.25 per share 25
“Our strong quarterly results reflect the breadth of our businesses and focused execution on our growth strategy, even in a dynamic environment. We continue to lead positive change and are addressing some of healthcare's biggest challenges. Our new market-defining rebate-free pharmacy benefit model will further lower costs and enhance transparency for the benefit of those we serve.”
Total revenues increased 10% to $69.7 billion, primarily driven by Evernorth Health Services growth 24
Cigna Healthcare MCR increased to 84.8% from 82.8% in Q3 2024, driven by Individual and Family Plans business and higher stop loss medical costs 24
Evernorth Health Services announced transformational rebate-free pharmacy benefit model designed to lower drug costs, improve transparency, and support local pharmacies 24
Net income more than doubled YoY (739.0 to USD 1,868.0 million, +153%). 23
Operating cash flow reached USD 3,418.0 million vs USD 46.0 million in 2024-Q3 (×74.3). 23
“Listening, adapting, and innovating to meet the evolving needs of our patients, customers, and clients enables us to deliver meaningful value. Our performance in the second quarter reflects our disciplined execution and the strength of our business mix.”
Total revenues increased 11% to $67.2 billion, primarily driven by Evernorth Health Services including growth of existing client relationships and strong specialty pharmacy growth 22
Cigna Healthcare MCR was 83.2% for Q2 2025 compared to 82.3% for Q2 2024, primarily due to expected higher stop loss medical costs 22
2025 outlook for adjusted income from operations of at least $29.60 per share reaffirmed 22
“We are building a more sustainable health care model by successfully delivering on our series of commitments and actions to improve transparency and support for our customers and patients. Our strong first quarter results and increase in outlook for full-year earnings reflects the strength of our Evernorth Health Services and Cigna Healthcare growth platforms in a dynamic environment.”
Cigna Healthcare MCR rose to 82.2% from 79.9% in Q1 2024, primarily driven by expected higher stop loss medical costs 20
2025 adjusted income from operations guidance raised to at least $29.60 per share 20
Divestiture of Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses to HCSC completed for $4.8 billion purchase price 19
2024 · 13 events
“While higher medical costs in our stop loss product impacted fourth quarter earnings, we are taking corrective actions to address these near-term pressures and we are simultaneously taking steps to further advance our long-term growth strategy. Through a dynamic environment, we are continuing to focus on building a sustainable model for healthcare by addressing the areas that matter most to our patients and clients, including greater transparency, support, and value.”
Q4 adjusted income from operations decreased 8% from Q4 2023, primarily driven by lower Cigna Healthcare contributions due to higher stop loss medical costs 17
Full year 2024 revenues +27% to $247.1B; total customer relationships increased 11% to 182.2 million and pharmacy customers grew 22% to 120.0 million driven by Evernorth Health Services expansion 17
Full year Cigna Healthcare MCR increased to 83.2% from 81.3% in 2023, primarily driven by higher stop loss medical costs, contributing to a 6% full-year decline in Cigna Healthcare adjusted income from operations 17
Operating cash flow reached USD 5,212.0 million vs USD 1,467.0 million in 2023-Q4 (×3.6). 125
“Our strong performance this quarter is a testament to the leadership, stability and expertise of our team. Our disciplined execution of our strategic plan and our comprehensive health services ensure we remain well-positioned in a highly dynamic environment, while sustaining business growth in both the near- and long-term.”
Q3 adjusted income from operations $7.51/share vs $6.77/share in Q3 2023, with Evernorth Health Services up 9% and Specialty and Care Services up 23%; Cigna Healthcare down 4% driven by higher MCR 16
Q3 shareholders' net income $2.63/share, reduced by a $1.0B non-cash after-tax investment loss from a second impairment of VillageMD equity securities 16
Q3 revenues +30% to $63.7B, driven by Evernorth Health Services large client wins, specialty volume growth, and increased Humira biosimilar adoption 16
“Our second quarter results underscore the strength of our diversified portfolio. We continue to deliver innovative solutions to meet the evolving needs of those we serve. We remain disciplined in our approach to executing our strategy, enabling us to consistently deliver value and sustain our growth in a dynamic environment.”
Q2 adjusted income from operations $6.72/share vs $6.13/share in Q2 2023, reflecting Evernorth Health Services growth of 30% in adjusted revenues and 7% in adjusted income 14
Q2 revenues +25% to $60.5B, driven by Evernorth Health Services Pharmacy Benefit Services reflecting large client wins including Centene and organic growth; Pharmacy Benefit Services adjusted revenues +41% 14
Cigna Healthcare MCR 82.3% in Q2, including approximately 40 bps of unfavorable prior-year Medicare Advantage risk adjustment revenue impacts 14
“Our strong first quarter results reflect the performance of our Evernorth and Cigna Healthcare businesses, as well as our leadership in addressing the evolving needs of those we serve with the breadth of our differentiated capabilities. Building on our track record of growth and continued momentum in 2024, we are pleased to increase our outlook for full-year earnings.”
Shareholders' net loss of $0.97/share in Q1, including a $1.8B non-cash after-tax investment loss from impairment of VillageMD equity securities 12
Q1 revenues +23% YoY, driven by Centene Corporation onboarding at the start of 2024, which increased pharmacy revenues 31% within Evernorth Health Services 11
Definitive agreement signed to sell Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses to Health Care Service Corporation for approximately $3.7 billion, expected to close Q1 2025 11
2023 · 13 events
“2023 was another very strong year for our company with consistent execution and sustained growth. We will accelerate our momentum in 2024 as we lead in improving value, affordability and clinical outcomes, as well as with expanding access and choice.”
Entered definitive agreement to sell Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits and CareAllies businesses to Health Care Service Corporation for $3.3 billion cash, subject to regulatory approvals (10)
Full-year 2023 revenues reached $195.3 billion, up from $180.5 billion in 2022; adjusted income from operations $7.4 billion ($25.09 per share) vs. $7.3 billion ($23.36 per share) in prior year (9)
2024 adjusted income from operations guidance initiated at at least $8.025 billion, or at least $28.25 per share (9)
“We continued to drive growth in the third quarter by harnessing our deep clinical expertise and service capabilities across our company, supporting high-quality care, improved affordability and better outcomes. With disciplined execution and continued innovation across Evernorth Health Services and Cigna Healthcare, we're meeting the evolving needs of those we serve.”
Adjusted income from operations increased 8% to $2.0 billion ($6.77 per share), reversing the year-over-year declines in Q1 and Q2 that had reflected the absence of businesses divested in the 2022 Chubb transaction (8)
Total revenues increased 8% to $49.0 billion; Evernorth Health Services adjusted revenues up 8% and Cigna Healthcare adjusted revenues up 14%, with premiums up 15% reflecting insured customer growth (8)
2023 adjusted EPS outlook raised to at least $24.75 per share from prior projection of at least $24.70 (8)
“We're pleased with our performance and growth across the breadth of our business in the second quarter as our co-workers continued to drive innovation and deliver effective and affordable solutions supporting the health and vitality of our customers, patients and clients.”
Total revenues increased 7% to $48.6 billion; Evernorth Health Services adjusted revenues up 10% and Cigna Healthcare adjusted revenues up 12%, driven by specialty growth and customer expansion (6)
2023 full-year adjusted revenue guidance raised to at least $190.0 billion; operating cash flow guidance raised to at least $9.5 billion (6)
Evernorth Health became minority owner in CarepathRx Health Systems Solutions through a $437 million equity method investment in July 2023 to provide integrated hospital pharmacy solutions (5)
“Our strong results in the first quarter demonstrate how our company continues to execute well, while also introducing innovative, market-leading solutions that improve clinical outcomes, affordability and transparency for the benefit of those we serve”
Total revenues increased 6% to $46.5 billion; Evernorth adjusted revenues up 8% and Cigna Healthcare adjusted revenues up 12%, reflecting specialty pharmacy growth and insured customer expansion (4)
Cigna Healthcare medical care ratio decreased 20 basis points to 81.3%, reflecting effective pricing execution and favorable cost trends including lower COVID-19 costs (3)
2023 adjusted income from operations outlook raised to at least $24.70 per share (4)
Operating cash flow reached USD 5,028.0 million vs USD 2,030.0 million in 2022-Q1 (×2.5). 3
Cigna Business Model
How Cigna (CI) makes its money, summarised from the filings up to Q2 2026, neutral and without forecast. NadirAlpha methodology
The Cigna Group is a global health services organization that operates through two principal segments. Evernorth Health Services delivers pharmacy benefit management through its Pharmacy Benefit Services unit and specialty pharmacy and care delivery through its Specialty and Care Services unit, serving employers, health plans, and government clients. Cigna Healthcare provides employer-sponsored medical, dental, behavioral health, and pharmacy benefits to U.S. commercial customers across National Accounts, Middle Market, and Select employer segments. Revenue is generated through insurance premiums, pharmacy revenues, and fees from benefit administration and service arrangements. Following the 2025 divestiture of Medicare Advantage and related government health businesses to HCSC, and with the announced January 2027 exit from Individual and Family Plans, the company is concentrating its health benefits franchise on commercial employer coverage while expanding pharmacy benefit management and care services through Evernorth.
Cigna Stock: Share-Price Drivers
What determines the business trajectory of Cigna according to management, summarised from the reports up to Q2 2026. NadirAlpha methodology
Evernorth's Pharmacy Benefit Services and Specialty and Care Services generate the large majority of group revenue and are expanding, lifting group revenue to USD 71,668 million in 2026-Q2 28
Pharmacy Benefit Services revenue is higher, supported by the multi-year Express Scripts and Centene Corporation pharmacy benefit management agreement that began onboarding in 2024 11; 18
Specialty and Care Services revenue is expanding, with the Shields Health Solutions investment and the EnGuide Pharmacy launch for GLP-1 medications adding to the platform 26
Cigna plans a rebate-free pharmacy benefit model targeted for 2027; still at the planning and business-plan stage with no traction reported yet 26; 24; 27
Cigna agreed to sell its Medicare Advantage and related businesses to HCSC 23 and plans to exit the Individual and Family Plans medical business from 1 January 2027, removing those revenue streams 29; 30
Cigna raised its dividend 9 and ran accelerated share repurchase agreements 13 while carrying net debt of USD 25,580 million at 2026-Q2 18
Cigna launched a Strategic Optimization Program and earlier Organizational Efficiency Plan aimed at operating efficiency 26; 9
Sector trend: Demand for pharmacy benefit management and specialty health services is rising, with Evernorth revenue growing and group revenue trending higher to USD 71,668 million in 2026-Q2 28. The managed-care insurance side is being narrowed as Cigna exits Medicare and Individual and Family Plans lines 23; 29.
Cigna Revenue by Type (as of 2026-Q2 · USD million · 4/6)
Where the revenue of Cigna comes from: segments and product types with share, growth and margin, as of Q2 2026, older structures remain in the expandable part. NadirAlpha methodology
| Segment | Since | Revenue | Growth | Margin | Source |
|---|---|---|---|---|---|
| Period 2026-Q2 (3M) | |||||
| Other Operations | 2023-Q1 | 131 | -29% | 16% | 29 |
| Period 2026-Q1 (3M) | |||||
| Pharmacy Benefit Services | 2024-Q1 | 33,002 | 11% | – | 28 |
| Specialty and Care Services | 2024-Q1 | 25,440 | 6% | – | 28 |
| Evernorth Health Services | 2022-Q2 | 58,442 | 9% | 2.5% | 28 |
| Period FY2024 (12M) | |||||
| Evernorth Health Services - Pharmacy Benefit Services | 2024-Q2 | 111,822 | 46% | – | 18 |
| Evernorth Health Services - Specialty and Care Services | 2024-Q2 | 90,333 | 18% | – | 18 |
Cigna Products & announcements (4/7 active+recent)
What Cigna launched, had approved or announced, from the filings up to Q2 2026, each row with the date of first mention. NadirAlpha methodology
Status: PlannedLaunched
| Product/Line | Since | Status | Source |
|---|---|---|---|
| 2026 | |||
| Rebate-free model business plan | 2026-03 | 27 | |
| 2025 | |||
| Rebate-free pharmacy benefit model (2x) | 2025-09 | 26 | |
| Strategic Optimization Program | 2025-03 | 26 | |
| EnGuide Pharmacy for GLP-1 medications | 2025 | 26 | |
| 2024 | |||
| DoD TRICARE Specialty Pharmacy expansion | 2024 | 10 | |
| 2023 | |||
| The Cigna Group Ventures strategic venture fund (2x) | 2023 | 18 | |
| Pathwell Bone & Joint product launch | 2023 | 10 | |
Cigna Transactions & Events (15)
15 transactions and events of Cigna from the original reports, financing measures and management changes are not listed here, cancelled items in grey. NadirAlpha methodology
Acquisitions by Cigna
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| 2025 | |||
| Shields Health Solutions investment | 2025-08 | Completed | 26 |
| 2024 | |||
| Centene Corporation Onboarding | 2024-01 | Completed | 11 |
| Organizational Efficiency Plan | 2024 | Completed | 9 |
| 2023 | |||
| VillageMD investment (6×) | 2023 | Completed | 18 |
| CarepathRx Health Systems Solutions minority ownership investment (2×) | 2023 | Completed | 5 |
Divestitures and exits by Cigna
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| 2027 | |||
| Exit from Individual and Family Plans medical business (2×) | 2027-01 | Divested | 29 |
| 2025 | |||
| HCSC transaction | 2025-03 | Divested | 26 |
| 2024 | |||
| HCSC transaction - Sale of Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, and CareAllies businesses (13×) | 2024-01 | Divested | 10 |
| Sale of Medicare businesses to HCSC (7×) | 2024 | Divested | 23 |
| 2023 | |||
| New York Life supplemental behavioral coverage contract non-renewal | 2023 | Divested | 8 |
| 2022 | |||
| Chubb transaction - sale of life, accident and supplemental health benefits business | 2022-07 | Divested | 7 |
| Joint venture in Türkiye divestiture | 2022 | Divested | 10 |
| Chubb international life insurance and supplemental benefits sale | 2022 | Divested | 10 |
Partnerships and contracts of Cigna
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| 2024 | |||
| Express Scripts and Prime Therapeutics LLC agreement for pharmacy network and specialty pharmacy services | 2024 | Agreement | 18 |
| Centene multi-year pharmacy benefit agreement (3×) | 2024 | Agreement | 18 |
Cigna Risks (90 since the annual report of 2026-02-26, 257 tracked in total)
Risk factors Cigna itself names in its reports, merged by topic across periods, with category, first mention and source; new risks of the latest period come first. NadirAlpha methodology
Category: MacroSupply chainMarketLegalESGTechnologyCustomersCompetitionRegulatoryCyberFinancialStrategyGeopolitics
| Risk | Category | Last reported |
|---|---|---|
| Cigna: first mention in 8-K-EX99.1 earnings release of 2026-07-30 (2026-Q2), source 30 | ||
| Ability to manage health care costs and respond to price competition, inflation and margin compression pressures. | = | |
| Cigna: first mention in 10-Q quarterly report of 2026-07-30 (2026-Q2), source 29 | ||
| Dependence on success of relationships with third parties and risk of disruption | = | |
| Ability to manage health care costs and respond to price competition, inflation and margin pressures | = | |
| Cigna: first mention in 8-K-EX99.1 earnings release of 2026-04-30 (2026-Q1), source 28 | ||
| Risk related to downgrade in financial strength ratings of insurance subsidiaries | 2026-Q2 2026-07-30 29 | |
| Cigna: first mention in 8-K-EX99.1 earnings release of 2024-05-02 (2024-Q1), source 12 | ||
| Compliance with applicable privacy, security and data laws, regulations and standards. | 2026-Q2 2026-07-30 30 | |
| Ability to prevent or contain effects of cyberattack or data security incident | 2026-Q2 2026-07-30 29 | |
| Cigna: first mention in 8-K-EX99.1 earnings release of 2024-02-02 (2023-Q4), source 9 | ||
| Ability to maintain relationships with key pharmaceutical manufacturers or if payments decline | 2026-Q2 2026-07-30 29 | |
| Ability to maintain relationships with key pharmaceutical manufacturers; potential for payment declines. | 2026-Q2 2026-07-30 30 | |
| Risks related to use of artificial intelligence and machine learning | 2026-Q2 2026-07-30 29 | |
| Ability to compete effectively and differentiate products and services in an evolving healthcare industry. | 2026-Q2 2026-07-30 30 | |
| Cigna: first mention in 10-Q quarterly report of 2023-08-03 (2023-Q2), source 5 | ||
| Substantial level of government regulation and potential effects of new or changed laws/regulations. | 2026-Q2 2026-07-30 30 | |
| Cigna: first mention in 8-K-EX99.1 earnings release of 2023-05-05 (2023-Q1), source 4 | ||
| Substantial level of government regulation and uncertainty around government-sponsored programs participation | 2026-Q2 2026-07-30 29 | |
| Ability to prevent or contain effects of cyberattacks or privacy/data security incidents. | 2026-Q2 2026-07-30 30 | |
| Impact of significant indebtedness and potential for further indebtedness | 2026-Q2 2026-07-30 29 | |
| Ability to develop and maintain relationships with payors, physicians, hospitals and health service providers. | 2026-Q2 2026-07-30 30 | |
| Ability to invest in and properly maintain information technology and business systems. | 2026-Q2 2026-07-30 30 | |
| Ability to compete effectively and differentiate products and services | 2026-Q2 2026-07-30 29 | |
| Cigna: first mention in 10-Q quarterly report of 2023-05-05 (2023-Q1), source 3 | ||
| Ability to develop and maintain satisfactory relationships with payors, physicians, hospitals and health service providers | 2026-Q2 2026-07-30 29 | |
| Outcome of litigation and regulatory audits and investigations | 2026-Q2 2026-07-30 29 | |
| Impact of changing interest rates | 2026-Q2 2026-07-30 29 | |
| Credit risk related to reinsurers | 2026-Q2 2026-07-30 29 | |
| Unfavorable economic and market conditions, recession or economic downturn impacting employment | 2026-Q2 2026-07-30 29 | |
| Compliance with privacy, security and data laws, regulations and standards | 2026-Q2 2026-07-30 29 | |
| Cigna: first mention in 8-K-EX99.1 earnings release of 2026-04-30 (2026-Q1), source 28 | ||
| potential liability in managing medical practices, operating pharmacies and onsite clinics | = | |
| substantial level of government regulation and potential effects of new or changed laws | = | |
| Cigna: first mention in 10-Q quarterly report of 2026-04-30 (2026-Q1), source 27 | ||
| ability to manage healthcare costs and respond to price competition, inflation and margin compression | 2026-Q1 2026-04-30 28 | |
| Compliance with privacy, security and data laws, regulations and standards; risk of cyberattack or data security incidents. | = | |
| Cigna: first mention in 10-K annual report of 2026-02-26 (FY2025), source 26 | ||
| Medical claims reserves based on extensive judgment and inherently variable; actual claims exceeding estimates could materially adversely affect results | = | |
| Noncompliance with complex Medicare and Medicaid regulations may result in significant fines, penalties, exclusion from programs and criminal penalties. | = | |
| Large client contract losses or unfavorable modifications to contract terms could adversely affect results of operations and trigger negative investment community reactions. | = | |
| Loss of customers from premium or fee increases could negatively impact business, cash flows, financial condition and results of operations. | = | |
| Evernorth Health Services has renewed contracts with three largest clients through end of decade; loss or material alteration could adversely affect results | = | |
| Networks comprise 65,000 pharmacies; geographic concentrations and short-notice terminations could reduce access or claims volume | = | |
| Failure to accurately predict and price health care costs could result in significant financial adverse impact; small differences between predicted and actual medical costs can materially change results. | = | |
| FTC settled all matters February 2026 without monetary penalty or fault finding; settlement requires business practice updates | = | |
| May be subject to future qui tam actions; indemnification obligations related to ongoing regulatory audits at HCSC transaction time | = | |
| Reinsurers may become financially unsound; inability to collect material recovery could materially adversely affect results | = | |
| Dividends from insurance subsidiaries subject to regulatory restrictions | = | |
| Failure to comply with regulatory requirements including data submission and claims payment could result in enrollment sanctions or contract termination | = | |
| Subject to extensive federal and state fraud waste and abuse laws; non-compliance could result in investigations and significant penalties | = | |
| Legislative reforms and regulatory actions related to rebates, reporting, owned pharmacies and other activities may adversely affect pricing ability and competitive position. | = | |
| HIPAA-regulated as business associate; voluntary 2025 OCR audit found no enforcement action but serious issues could trigger compliance reviews | = | |
| Currently subject to litigation claiming improper use of AI in claims evaluation process; regulatory restrictions could impact business efficiency | = | |
| Subject to frequent cyberattacks including ransomware; Change Healthcare attack in February 2024 caused service disruption | = | |
| Macro economic uncertainties could impact debt security portfolio credit quality | = | |
| Private placement securities require greater judgment in fair value measurement | = | |
| Unfavorable economic conditions could reduce enrollment demand and increase provider medical costs | = | |
| Ongoing geopolitical events and economic conditions impacting debt issuer credit quality | = | |
| Congressional Budget Reconciliation Act of 2025 includes provisions expected to reduce federal Medicaid spending and modify eligibility. | = | |
| Participation in health insurance exchanges involves uncertainties associated with business mix and volume. | = | |
| Foreign operations subject to Foreign Corrupt Practices Act and similar anti-corruption laws; violations may result in severe criminal and civil sanctions. | = | |
| Complex health care fraud, waste and abuse laws prohibit wide range of activities; noncompliance may result in civil and criminal penalties and exclusion from programs. | = | |
| Business model impacted by ACA and potential future changes; ACA subsidy provisions expired December 31, 2025. | = | |
| Enhanced cybersecurity requirements for government contractors including CMMC compliance, FISMA, and Executive Order requirements phasing in through 2028. | = | |
| Multiple federal and state privacy laws including HIPAA, state health data privacy laws, and comprehensive state privacy laws impose restrictions on data collection and use. | = | |
| Decreasing reimbursement rates, payment delays, or insufficient increases in government program reimbursement rates could impact financial results. | = | |
| Insurance holding company laws require registration, disclosure of enterprise risk information and approvals of dividends and affiliate transactions. | = | |
| Foreign operations subject to bribery corruption and money laundering laws; violations could result in fines and restrictions | = | |
| International operations subject to multiple jurisdictions with potentially more stringent requirements including GDPR, EU AI Act, data residency regulations and anti-corruption laws. | = | |
| Failure to satisfy prescribed minimum medical loss ratio requirements may require premium refunds to policyholders. | = | |
| Numerous PBM regulations govern disclosure of rebates, pharmacy contracting practices, MAC pricing, formulary administration and other operational aspects. | = | |
| Required to obtain and maintain approvals for price increases and geographic expansion; delays could reduce revenue or increase costs | = | |
| Federal and state regulatory agencies may restrict or prevent implementation of premium rate changes or collection of certain administrative fees. | = | |
| RBC and non-U.S. surplus rules impose minimum capital requirements with potential regulatory actions if ratios fall below minimum. | = | |
| Competitors may have greater resources and lower profit margin expectations; failure to demonstrate value could reduce competitiveness | = | |
| Strong competition in pharmacy benefit business generates demand for lower pricing and greater revenue sharing, applying pressure on operating margins. | = | |
| Cigna: first mention in 10-K annual report of 2025-02-27 (FY2024), source 18 | ||
| $1.5 billion in uncertain tax positions could require future tax payments | FY2025 2026-02-26 26 | |
| CMS granted ability to negotiate drug prices for Medicare Part D and B drugs; legislative proposals could impact pricing strategies and margins | FY2025 2026-02-26 26 | |
| FTC and state regulators increasingly focused on use of AI and data; AI remains FTC enforcement priority with multiple state regulations and guidance issued. | FY2025 2026-02-26 26 | |
| Weak office sector fundamentals impacting commercial mortgage loan valuations | FY2025 2026-02-26 26 | |
| Cigna: first mention in 8-K-EX99.1 earnings release of 2024-10-31 (2024-Q3), source 16 | ||
| Changes in earnings projections could trigger goodwill or intangible asset impairment | FY2025 2026-02-26 26 | |
| Cigna: first mention in 8-K-EX99.1 earnings release of 2024-08-01 (2024-Q2), source 14 | ||
| Risk of downgrade in financial strength ratings of insurance subsidiaries. | 2026-Q1 2026-04-30 27 | |
| Cigna: first mention in 8-K-EX99.1 earnings release of 2024-05-02 (2024-Q1), source 12 | ||
| risks related to strategic transactions and realization of expected benefits, integration difficulties | 2026-Q1 2026-04-30 28 | |
| Potential liability in managing medical practices, pharmacies, onsite clinics and medical facilities | 2025-Q1 2025-05-02 19 | |
| risk of significant disruption within operations or among key suppliers or third parties | 2026-Q1 2026-04-30 28 | |
| Cigna: first mention in 10-Q quarterly report of 2024-05-02 (2024-Q1), source 11 | ||
| Total indebtedness approximately $31.5 billion as of December 31, 2025; debt service limits cash available for growth and dividends | FY2025 2026-02-26 26 | |
| Credit risk related to reinsurers. | 2026-Q1 2026-04-30 27 | |
| Cigna: first mention in 10-K annual report of 2024-02-29 (FY2023), source 10 | ||
| State legislation and regulations prohibit certain network restrictions and mandate coverage of certain benefits; one state law prohibiting PBM ownership of pharmacies impacts vertically integrated entities. | FY2025 2026-02-26 26 | |
| Fixed-income portfolio exposed to interest rate changes affecting fair values | FY2025 2026-02-26 26 | |
| Currently overfunded frozen pension plan; significant stock market or interest rate declines could increase expenses and funding needs | FY2025 2026-02-26 26 | |
| Cigna: first mention in 8-K-EX99.1 earnings release of 2024-02-02 (2023-Q4), source 9 | ||
| compliance with privacy, security and data laws, regulations and standards | 2026-Q1 2026-04-30 28 | |
| Cigna: first mention in 10-Q quarterly report of 2023-11-02 (2023-Q3), source 7 | ||
| Unfavorable economic and market conditions, recession or economic downturn affecting employment and stock market. | 2026-Q1 2026-04-30 27 | |
| Outcome of litigation, regulatory audits and investigations | 2025-Q1 2025-05-02 20 | |
| Cigna: first mention in 10-Q quarterly report of 2023-08-03 (2023-Q2), source 5 | ||
| credit risk related to reinsurers | 2026-Q1 2026-04-30 28 | |
| Cigna: first mention in 8-K-EX99.1 earnings release of 2023-05-05 (2023-Q1), source 4 | ||
| Risks related to strategic transactions and realization of expected benefits; integration or separation difficulties. | 2025-Q2 2025-07-31 21 | |
| potential for actual claims to exceed estimates related to expected medical claims | 2026-Q1 2026-04-30 28 | |
| changes in pharmacy provider marketplace or pharmacy networks | 2026-Q1 2026-04-30 28 | |
| Outcome of litigation, regulatory audits and investigations. | 2026-Q1 2026-04-30 27 | |
| Cigna: first mention in 10-Q quarterly report of 2023-05-05 (2023-Q1), source 3 | ||
| political, legal, operational, regulatory and economic risks affecting multinational operations including currency exchange | 2026-Q1 2026-04-30 28 | |
| ability to prevent or contain effects of cyberattack or data security incident | 2026-Q1 2026-04-30 28 | |
Cigna Reported KPIs (as disclosed) (360)
Figures Cigna discloses itself in addition to the standard financials, such as order intake, recurring revenue or unit counts, as reported and with no calculation of our own. NadirAlpha methodology
| KPI | Value / change | Source |
|---|---|---|
| Cigna, published 2026-07-30, period 2026-Q2 | ||
| Unpaid claims and claim expenses | 5,228 | 29 |
| Undrawn committed capacity under revolving credit agreement | 6.5 | 29 |
| Total revenues | 71,668 | 29 |
| Total medical customers | 18,413 | 29 |
| Total Pharmacy Customers | 118,243 | 30 |
| Total Medical Customers | 18,413 | 30 |
| Total Customer Relationships | 182,765 | 30 |
| Share repurchases | 250 | 29 |
| Premiums | 9,859 | 29 |
| Pharmacy revenues | 57,172 | 29 |
| Other long-term investments | 5.2 | 29 |
| Net investment income | 272 | 29 |
| Medical care ratio | 84.5% | 29 |
| Fees and other revenues | 4,365 | 29 |
| Dental Customers | 18,488 | 30 |
| Debt-to-capitalization ratio | 42.8% | 29 |
| Debt securities portfolio carrying value | 8.5 | 29 |
| Commercial paper program outstanding balance | 1.0 | 29 |
| Commercial mortgage loan portfolio | 1.2 | 29 |
| Cigna Healthcare Medical Care Ratio | 84.5% | 30 |
| Cash and short-term investments | 6.6 | 29 |
| Capital expenditures | 0.6 | 29 |
| Behavioral Care Customers | 27,621 | 30 |
| Cigna, published 2026-04-30, period 2026-Q1 | ||
| Unpaid claims and claim expenses | $4,920 | 27 |
| Undrawn committed capacity revolving credit | $6.5 billion | 27 |
| Other long-term investments | $5.2 billion | 27 |
| Medical customers total | 18,334 | 27 |
| Debt to capitalization ratio | 42.3% | 27 |
| Commercial mortgage loan portfolio | $1.3 billion | 27 |
| Cash and short-term investments | $7.3 billion | 27 |
| Total Pharmacy Customers | 121,020 | 28 |
| Total Medical Customers | 18,334 | 28 |
| Total Customer Relationships | 185,470 | 28 |
| Specialty and Care Services Adjusted Revenues | 25,440 | 28 |
| Shareholders' Equity Per Share | 159.59 | 28 |
| Shareholders' Equity | 42,210 | 28 |
| SG&A Expense Ratio | 5.4% | 28 |
| Pharmacy Benefit Services Adjusted Revenues | 33,002 | 28 |
| Evernorth Health Services Adjusted Revenues | 58,442 | 28 |
| Debt-to-Capitalization Ratio | 42.3% | 28 |
| Cigna Healthcare Medical Care Ratio | 79.8% | 28 |
| Cigna Healthcare Adjusted Revenues | 11,477 | 28 |
| Adjusted SG&A Expense Ratio | 4.8% | 28 |
| Cigna, published 2026-02-26, period FY2025 | ||
| Voluntary Turnover Rate | 9% | 26 |
| US Patents | over 540 | 26 |
| US Network Physicians | 1.7 million | 26 |
| US Network Hospitals | over 6,000 | 26 |
| US Federal Government Revenue % | 11% | 26 |
| US Federal Government Revenue % | 15% | 26 |
| US Ethnic Minorities % | 40% | 26 |
| Underrepresented-to-White Wage Ratio US | more than 99 cents per dollar | 26 |
| Specialty Pharmacies | 35 licensed pharmacies | 26 |
| Specialist Group Arrangements | approximately 100 | 26 |
| Single Pharmacy Benefit Client Revenue % | 19% | 26 |
| Single Pharmacy Benefit Client Revenue % | 16% | 26 |
| Primary Care Value-Based Arrangements | more than 200 | 26 |
| Pharmacy Claims Processing Capacity | over two billion adjusted prescriptions annually | 26 |
| Pharmaceutical Purchases Single Wholesaler % | approximately 50% | 26 |
| markets and jurisdictions | more than 30 | 26 |
| insured segment revenue percentage | 68% | 26 |
| insured medical customers percentage | 21% | 26 |
| individual family plans states | 11 states | 26 |
| hospital system hospitals covered | more than 750 | 26 |
| hospital system contracts | more than 200 | 26 |
| home delivery pharmacy locations | 11 licensed pharmacies | 26 |
| home delivery pharmacy fulfillment centers | 4 | 26 |
| healthcare providers relationships | 1.7 million | 26 |
| health system services distribution centers | 4 | 26 |
| health benefits payroll investment percentage | 20% | 26 |
| female to male wage ratio US | more than 99 cents per dollar | 26 |
| female to male wage ratio global | more than 99 cents per dollar | 26 |
| Express Scripts rebate sharing percentage | over 95% | 26 |
| Express Scripts clients receiving 100 percent rebates | more than two-thirds | 26 |
| Enguide pharmacy locations | 2 licensed pharmacies | 26 |
| Enguide pharmacy fulfillment centers | 1 | 26 |
| dental IFP states | 49 states | 26 |
| customer relationships | 185 million | 26 |
| ASO segment revenue percentage | 32% | 26 |
| ASO medical customers percentage | 79% | 26 |
| Unpaid claims and claim expenses | $4,241 | 26 |
| Undrawn committed capacity | $6.5 billion | 26 |
| Total medical customers | 18,118 | 26 |
| Debt to capitalization ratio | 43.0% | 26 |
| Cigna, published 2026-02-05, period 2025-Q4 | ||
| Total Pharmacy Customers | 123,603 | 25 |
| Total Medical Customers | 18,118 | 25 |
| Total Customer Relationships | 188,428 | 25 |
| Shareholders' Equity per Share | $158.33 | 25 |
| SG&A Expense Ratio | 5.0% | 25 |
| SG&A Expense Ratio | 5.3% | 25 |
| Dental Customers | 18,438 | 25 |
| Debt-to-Capitalization Ratio | 43.0% | 25 |
| Cigna Healthcare Medical Care Ratio | 88.0% | 25 |
| Cigna Healthcare Medical Care Ratio | 84.4% | 25 |
| Behavioral Care Customers | 28,269 | 25 |
| Adjusted SG&A Expense Ratio | 4.7% | 25 |
| Adjusted SG&A Expense Ratio | 5.0% | 25 |
| Cigna, published 2025-10-30, period 2025-Q3 | ||
| Unpaid claims and claim expenses | $4,676 | 23 |
| Total Pharmacy Customers | 122,486 | 24 |
| Total Medical Customers | 18,059 | 24 |
| Total Customer Relationships | 182,490 | 24 |
| Medical customers | 18,059 | 23 |
| Debt-to-capitalization ratio | 44.9% | 23 |
| Cigna Healthcare Medical Care Ratio | 84.8% | 24 |
| Cigna, published 2025-07-31, period 2025-Q2 | ||
| Total revenues (3 months) | 67,178 | 21 |
| Total revenues (6 months) | 132,680 | 21 |
| Total income taxes (3 months) | 389 | 21 |
| Total income taxes (6 months) | 628 | 21 |
| Shareholders' net income (3 months) | 1,532 | 21 |
| Shareholders' net income (6 months) | 2,855 | 21 |
| Premiums (3 months) | 9,156 | 21 |
| Premiums (6 months) | 21,892 | 21 |
| Pharmacy revenues (3 months) | 53,649 | 21 |
| Pharmacy revenues | 102,282 | 21 |
| Pharmacy and other service costs | 53,268 | 21 |
| Pharmacy and other service costs | 101,666 | 21 |
| Net investment income | 236 | 21 |
| Net investment income | 474 | 21 |
| Net investment gains/losses | 52 | 21 |
| Net investment gains/losses | 50 | 21 |
| Net income | 1,632 | 21 |
| Net income | 3,041 | 21 |
| Net income attributable to noncontrolling interests | 100 | 21 |
| Net income attributable to noncontrolling interests | 186 | 21 |
| Medical customers thousands | 18,046 | 21 |
| Medical costs and other benefit expenses | 7,749 | 21 |
| Medical costs and other benefit expenses | 18,247 | 21 |
| Interest expense and other | (337) | 21 |
| Interest expense and other | (699) | 21 |
| Income from operations | 2,306 | 21 |
| Income from operations | 4,277 | 21 |
| Income before income taxes | 2,021 | 21 |
| Income before income taxes | 3,669 | 21 |
| Gain (Loss) on Sale of Businesses (3M) | – | 21 |
| Gain (Loss) on Sale of Businesses (6M) | 41 | 21 |
| Fees and Other Revenues (3M) | 4,137 | 21 |
| Fees and Other Revenues (6M) | 8,032 | 21 |
| Effective Tax Rate (3M) | 19.2 % | 21 |
| Effective Tax Rate (6M) | 17.1 % | 21 |
| Consolidated Effective Tax Rate 2024 (3M) | 18.1 % | 21 |
| Consolidated Effective Tax Rate 2024 (6M) | 31.5 % | 21 |
| Total Pharmacy Customers | 121,892 | 22 |
| Total medical customers | 18,046 | 22 |
| Total Customer Relationships | 182,236 | 22 |
| Cigna Healthcare Medical Care Ratio | 83.2% | 22 |
| Cigna, published 2025-05-02, period 2025-Q1 | ||
| Unpaid claims and claim expenses | 4,508 | 19 |
| U.S. Healthcare Medical Customers | 16,364 | 20 |
| Total Pharmacy Customers | 122,283 | 20 |
| Total Medical Customers | 18,043 | 20 |
| Total Customer Relationships | 182,208 | 20 |
| SG&A Expense Ratio | 6.4% | 20 |
| Medical customers | 18,043 | 19 |
| International Health Medical Customers | 1,679 | 20 |
| Evernorth Health Services Margin, Pre-Tax | 2.7% | 20 |
| Dental Customers | 18,466 | 20 |
| Debt-to-capitalization ratio | 43.1% | 19 |
| Cigna Healthcare Medical Care Ratio | 82.2% | 20 |
| Cigna Healthcare Margin, Pre-Tax | 8.9% | 20 |
| Behavioral Care Customers | 23,416 | 20 |
| Adjusted SG&A Expense Ratio | 5.8% | 20 |
| Cigna, published 2025-02-27, period FY2024 | ||
| Voluntary Turnover Rate | approximately 9% | 18 |
| U.S. Physician Network | approximately 1.8 million | 18 |
| US Patents | over 480 | 18 |
| U.S. Federal Government Revenue 2024 (%) | approximately 11% | 18 |
| U.S. Federal Government Revenue 2023 (%) | 15% | 18 |
| U.S. Federal Government Revenue 2022 (%) | 14% | 18 |
| Specialty Pharmacies | 35 licensed pharmacies | 18 |
| single pharmacy client revenue percentage | approximately 16% | 18 |
| settlement annuity guaranteed payments percentage | approximately 12% | 18 |
| retail pharmacy networks | national and regional network options | 18 |
| provider value based arrangements specialist | approximately 100 | 18 |
| provider value based arrangements primary care | more than 200 | 18 |
| payroll invested in benefits percentage | approximately 19% | 18 |
| medicare supplement plans states | 48 states and the District of Columbia | 18 |
| medicare advantage plans states | 29 states and the District of Columbia | 18 |
| insured segment revenue percentage | approximately 74% | 18 |
| insured medical customers percentage | 26% | 18 |
| ifp plans states | 11 states | 18 |
| hospitals in contracts | more than 800 | 18 |
| hospital system contracts | more than 200 | 18 |
| hospital network | over 6,000 | 18 |
| home delivery pharmacies | 13 licensed pharmacies, including 4 fulfillment pharmacies | 18 |
| ethnic minority pay equity us | more than 99 cents | 18 |
| dental ifp plans states | 49 states | 18 |
| customer patient relationships | approximately 182 million | 18 |
| cigna ventures commitment | 700 million | 18 |
| centene rebates shared percentage | over 95% | 18 |
| centene clients 100pct rebates percentage | more than two-thirds | 18 |
| ASO Segment Revenue % | approximately 26% | 18 |
| ASO Medical Customers % | 74% | 18 |
| Adjusted Prescriptions Annually | over 2 billion | 18 |
| Valuation Allowances | $2,332 million | 18 |
| Valuation Allowances | $1,498 million | 18 |
| Unpaid Claims Net | $4,859 million | 18 |
| Unpaid Claims Net | $4,856 million | 18 |
| Unpaid Claims Gross | $5,018 million | 18 |
| Unpaid Claims Gross | $5,092 million | 18 |
| Undrawn Committed Capacity | $6.5 billion | 18 |
| Uncertain Tax Positions | $1.5 billion | 18 |
| Total Share Repurchase Authority | $10.3 billion | 18 |
| Tax Position Balances | $1,477 million | 18 |
| Tax Position Balances | $1,399 million | 18 |
| Subsidiary Borrowing Capacity | $1.8 billion | 18 |
| Shares Repurchased 2025 YTD | 3.0 million | 18 |
| Shares Repurchased | 20.9 million | 18 |
| Shares Repurchased | 7.8 million | 18 |
| Share Repurchase Amount 2025 YTD | $901 million | 18 |
| Share Repurchase Amount | $7.0 billion | 18 |
| Share Repurchase Amount | $2.3 billion | 18 |
| Service Commitments | $0.7 billion | 18 |
| Remaining Share Repurchase Authority | $9.4 billion | 18 |
| Remaining Commercial Paper Capacity | $5.6 billion | 18 |
| Purchase Obligations Total | $4.2 billion | 18 |
| Purchase Obligations Next | $1.6 billion | 18 |
| Potential Tax Payments | $1.0 billion | 18 |
| Parent Company Cash | $0.8 billion | 18 |
| Other Long Term Investments | $4.6 billion | 18 |
| Medical customers | 19,147 | 18 |
| Long Term Debt Scheduled Payments | $48.5 billion | 18 |
| Long Term Debt Due | $3.5 billion | 18 |
| Investment Grade Debt Securities | $8.1 billion | 18 |
| Investment Commitments | $0.9 billion | 18 |
| Investment Commitments | $2.7 billion | 18 |
| HCSC Transaction Initial Price | $3.3 billion | 18 |
| Future Service Commitments | $1.5 billion | 18 |
| Expected Capex | $1.4 billion | 18 |
| Dividends from US Subsidiaries | $2.4 billion | 18 |
| Dividends from US Subsidiaries | $1.2 billion | 18 |
| Debt to Capitalization Ratio | 43.8% | 18 |
| Debt to Capitalization Ratio | 40.1% | 18 |
| Debt Securities Portfolio | $9.4 billion | 18 |
| Debt Securities | $9.9 billion | 18 |
| Commercial Paper Outstanding | $0.9 billion | 18 |
| Commercial Mortgage Loan Portfolio | $1.4 billion | 18 |
| China Joint Venture Investment Portfolio | $15.6 billion | 18 |
| Cash and Short-Term Investments | $7.6 billion | 18 |
| Capital Expenditures | $1.4 billion | 18 |
| Capital Expenditures | $1.6 billion | 18 |
| Below Investment Grade Debt Securities | $1.3 billion | 18 |
| Cigna, published 2025-01-30, period 2024-Q4 | ||
| Total Pharmacy Customers | 118,304 | 17 |
| Total Medical Customers | 19,147 | 17 |
| Total Customer Relationships | 182,212 | 17 |
| Specialty and Care Services Adjusted Revenues | 23,471 | 17 |
| Specialty and Care Services Adjusted Revenues, Full Year | 90,333 | 17 |
| Specialty and Care Services Adjusted Income from Operations Pre-Tax | 948 | 17 |
| Specialty and Care Services Adjusted Income from Operations Pre-Tax, Full Year | 3,424 | 17 |
| Pharmacy Benefit Services Adjusted Revenues | 30,273 | 17 |
| Pharmacy Benefit Services Adjusted Revenues, Full Year | 111,822 | 17 |
| Pharmacy Benefit Services Adjusted Income from Operations Pre-Tax | 1,198 | 17 |
| Pharmacy Benefit Services Adjusted Income from Operations Pre-Tax, Full Year | 3,577 | 17 |
| Evernorth Health Services Adjusted Revenues | 53,744 | 17 |
| Evernorth Health Services Adjusted Revenues, Full Year | 202,155 | 17 |
| Evernorth Health Services Adjusted Income from Operations Pre-Tax | 2,146 | 17 |
| Evernorth Health Services Adjusted Income from Operations Pre-Tax, Full Year | 7,001 | 17 |
| Cigna Healthcare MCR | 87.9% | 17 |
| Cigna Healthcare MCR, Full Year | 83.2% | 17 |
| Cigna Healthcare Adjusted Revenues | 13,331 | 17 |
| Cigna Healthcare Adjusted Revenues, Full Year | 52,914 | 17 |
| Cigna Healthcare Adjusted Income from Operations Pre-Tax | 511 | 17 |
| Cigna Healthcare Adjusted Income from Operations Pre-Tax, Full Year | 4,229 | 17 |
| Cigna, published 2024-10-31, period 2024-Q3 | ||
| Pharmacy claim volume | 531 | 15 |
| Medical customers | 19,048 | 15 |
| Adjusted revenues | 63,699 | 15 |
| Total Pharmacy Customers | 119,996 | 16 |
| Total Medical Customers | 19,048 | 16 |
| Total Customer Relationships | 183,514 | 16 |
| SG&A Expense Ratio | 5.6% | 16 |
| Medicare Part D Customers | 2,557 | 16 |
| Dental Customers | 18,251 | 16 |
| Cigna Healthcare Medical Care Ratio | 82.8% | 16 |
| Behavioral Care Customers | 23,662 | 16 |
| Adjusted SG&A Expense Ratio | 5.5% | 16 |
| Cigna, published 2024-08-01, period 2024-Q2 | ||
| Unpaid claims and claim expenses Cigna Healthcare | 5202 | 13 |
| Undrawn revolving credit capacity | 6500 | 13 |
| Total Pharmacy Customers | 122,470 | 14 |
| Total Medical Customers | 19,043 | 14 |
| Total Customer Relationships | 186,232 | 14 |
| Shareholders' Equity per Share | $147.87 | 14 |
| Shareholders' Equity | $41,332 | 14 |
| SG&A Expense Ratio | 6.1% | 14 |
| Medicare Part D Customers | 2,564 | 14 |
| Medical customers | 19043 | 13 |
| Dental Customers | 18,339 | 14 |
| Debt-to-Capitalization Ratio | 43.6% | 14 |
| Debt to capitalization ratio | 43.6% | 13 |
| Commercial paper outstanding | 790 | 13 |
| Cigna Healthcare Medical Care Ratio | 82.3% | 14 |
| Cash and short-term investments | 7000 | 13 |
| Behavioral Care Customers | 23,816 | 14 |
| Adjusted SG&A Expense Ratio | 6.0% | 14 |
| Cigna, published 2024-05-02, period 2024-Q1 | ||
| Total Pharmacy Customers | 122,767 | 12 |
| Total Medical Customers | 19,184 | 12 |
| Total Customer Relationships | 186,753 | 12 |
| Shareholders' Equity per Share | 145.00 | 12 |
| Shareholders' Equity | 41,181 | 12 |
| Pre-tax adjusted margin Evernorth | 2.9% | 11 |
| Pre-tax adjusted margin Cigna Healthcare | 10.1% | 11 |
| Medicare Part D Customers | 2,558 | 12 |
| Medical customers | 19184 | 11 |
| Medical care ratio Cigna Healthcare | 79.9% | 11 |
| Dental Customers | 18,443 | 12 |
| Cigna Healthcare MCR | 79.9% | 12 |
| Behavioral Care Customers | 23,801 | 12 |
| Adjusted Expense Ratio Evernorth | 2.1% | 11 |
| Adjusted Expense Ratio Cigna Healthcare | 20.5% | 11 |
| Cigna, published 2024-02-29, period FY2023 | ||
| Pre-Tax Adjusted Margin Other Operations | 16.1% | 10 |
| Pre-Tax Adjusted Margin Evernorth | 4.2% | 10 |
| Pre-Tax Adjusted Margin Cigna | 8.7% | 10 |
| Overall Generic Fill Rate | 86.7% | 10 |
| Network Generic Fill Rate | 86.9% | 10 |
| Medical Care Ratio Cigna | 81.3% | 10 |
| Home Delivery Generic Fill Rate | 85.3% | 10 |
| Adjusted Expense Ratio Evernorth | 2.2% | 10 |
| Adjusted Expense Ratio Cigna | 21.6% | 10 |
| Medical customers | 19,780 | 10 |
| Cigna, published 2024-02-02, period 2023-Q4 | ||
| U.S. Healthcare | 18.170 million | 9 |
| Total Pharmacy Customers | 98.6 million | 9 |
| Total Medical Customers | 19.8 million | 9 |
| Total Customer Relationships | 164.399 million | 9 |
| Medicare Part D | 2.550 million | 9 |
| International Health | 1.610 million | 9 |
| Dental | 18.543 million | 9 |
| Debt-to-Capitalization Ratio | 40.1% | 9 |
| Cigna Healthcare Medical Care Ratio | 82.2% | 9 |
| Cigna Healthcare Medical Care Ratio | 81.3% | 9 |
| Behavioral Care | 24.956 million | 9 |
| Cigna, published 2023-11-02, period 2023-Q3 | ||
| Total Revenues | $49,048 | 7 |
| Shareholders Net Income | $1,408 | 7 |
| Medical customers | 19,607 | 7 |
| Adjusted revenues | $49,078 | 7 |
| Total Pharmacy Customers | 98,325 | 8 |
| Total Medical Customers | 19,607 | 8 |
| Total Customer Relationships | 164,169 | 8 |
| Shareholders' Equity per Share | $155.54 | 8 |
| Evernorth Health Services Adjusted Margin, Pre-Tax | 4.4% | 8 |
| Debt-to-Capitalization Ratio | 40.5% | 8 |
| Cigna Healthcare Medical Care Ratio | 80.5% | 8 |
| Cigna Healthcare Adjusted Margin, Pre-Tax | 9.6% | 8 |
| Adjusted SG&A Expense Ratio | 7.3% | 8 |
| Cigna, published 2023-08-03, period 2023-Q2 | ||
| Unpaid Claims and Claim Expenses - Cigna Healthcare | 5,336 | 5 |
| Total Pharmacy Customers | 98,638 | 6 |
| Total Medical Customers | 19,506 | 6 |
| Total Customer Relationships | 165,703 | 6 |
| SG&A Expense Ratio | 7.1% | 6 |
| Medical customers | 19,506 | 5 |
| Evernorth Adjusted Margin, Pre-Tax | 4.0% | 6 |
| Debt-to-capitalization ratio | 41.9% | 6 |
| Cigna Healthcare MCR | 81.2% | 6 |
| Cigna Healthcare Adjusted Margin, Pre-Tax | 9.2% | 6 |
| Cigna, published 2023-05-05, period 2023-Q1 | ||
| Total Pharmacy Customers | 98,749 | 4 |
| Total Medical Customers | 19,473 | 4 |
| Total Customer Relationships | 166,384 | 4 |
| Share Repurchases YTD | 3.7 million shares | 4 |
| Medicare Part D Customers | 2,541 | 4 |
| Medical customers | 19,473 | 3 |
| Diluted Earnings Per Share | 4.24 | 3 |
| Dental Customers | 18,731 | 4 |
| Debt-to-Capitalization Ratio | 42.2% | 4 |
| Cigna Healthcare MCR | 81.3% | 4 |
| Behavioral Care Customers | 26,890 | 4 |
| Adjusted Revenues | 46,479 | 3 |
Cigna Development
The business development of Cigna period by period up to Q2 2026, each text from the original report of that period, source numbers lead to the source. NadirAlpha methodology
FY2026: Cigna
In the first half of fiscal year 2026, Cigna reported total revenues of USD 68,494 million in the first quarter and USD 71,668 million in the second quarter, with growth driven primarily by Evernorth Health Services pharmacy volumes and higher premiums within Cigna Healthcare 28 30. Cigna's shareholders' net income reached USD 1,654 million in the first quarter, a 25% increase versus the prior-year period, and USD 1,660 million in the second quarter, an 8% increase, primarily reflecting higher adjusted income from operations in Cigna Healthcare 27 29. First-quarter premiums decreased 23% and Cigna Healthcare adjusted revenues decreased 21%, primarily driven by the completion of the HCSC transaction on March 19, 2025, which transferred Medicare Advantage and related businesses; excluding divested businesses, Cigna Healthcare revenues grew 8% in the first quarter 27 28. In April 2026, Cigna announced its planned exit from the Individual and Family Plans medical business effective January 1, 2027 29. The company raised its full-year 2026 outlook for adjusted income from operations per share twice during the first half, reaching at least $30.45 per share as of the second-quarter earnings report 30.
FY2025: Cigna
The Cigna Group reported full-year 2025 revenues of $274.9 billion, an increase of 11% year-over-year, driven primarily by growth in Evernorth Health Services, where pharmacy revenues rose 17% to $216,672 million (26). On March 19, 2025, the company completed the divestiture of its Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses to Health Care Service Corporation for $4.9 billion in cash proceeds, reducing total medical customers by 5% to 18,118 thousand (26). Shareholders' net income increased 73% to $5,957 million ($22.18 per share), primarily reflecting the absence of a non-cash impairment of VillageMD equity securities recorded in 2024; on an adjusted basis, income from operations increased 4% to $8,014 million ($29.84 per share) (26). The Cigna Healthcare segment's medical care ratio rose 120 basis points to 84.4% for the full year, primarily driven by the Individual and Family Plans business (26). In Q3 2025, Evernorth Health Services announced a transformational rebate-free pharmacy benefit model, and the company subsequently established a 2026 adjusted income from operations outlook of at least $7.950 billion ($30.25 per share) (24, 25).
FY2024: Cigna
The Cigna Group reported FY2024 total revenues of $247.1 billion, a 27% increase from 2023, driven primarily by 32% growth in Evernorth Health Services following the onboarding of Centene Corporation at the start of the year and strong specialty volume growth across pharmacy and specialty businesses 17 18. Adjusted income from operations rose 4% to $7.7 billion ($27.33 per diluted share), as Evernorth Health Services earnings grew 9% while Cigna Healthcare adjusted income from operations declined 6% due to a higher medical care ratio 17. Shareholders' net income of $3.4 billion ($12.12 per diluted share) was materially reduced by $2.7 billion in aggregate non-cash after-tax investment losses from successive impairments of VillageMD equity securities recorded across 2024 17. In January 2024, the Company entered a definitive agreement to divest its Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses to Health Care Service Corporation for approximately $3.7 billion, with closing expected in Q1 2025 17 18. The Cigna Healthcare medical care ratio increased 190 basis points to 83.2% for the full year, primarily driven by higher stop loss medical costs 17 18.
FY2023: Cigna
The Cigna Group reported full-year 2023 total revenues of $195.3 billion, up from $180.5 billion in 2022, with Evernorth Health Services contributing adjusted revenues of $153.5 billion and Cigna Healthcare contributing adjusted revenues of $51.2 billion (9, 10). Adjusted income from operations reached $7.4 billion, or $25.09 per share, compared with $7.3 billion, or $23.36 per share, in 2022, driven by higher earnings in both reportable segments (9). Shareholders' net income of $5.16 billion ($17.39 per share) was reduced by an estimated loss recognized in connection with the definitive agreement to sell Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits and CareAllies businesses to Health Care Service Corporation for $3.3 billion cash, partially offset by foreign deferred tax benefits (10, 18). Medical customers grew 10% to 19.8 million and pharmacy customers grew 5% to 98.6 million at December 31, 2023, while the company repurchased approximately $2.3 billion in shares and declared a 14% increase in the quarterly dividend (9). Strategic investments during 2023 included a $2.7 billion preferred equity stake in VillageMD and a minority interest in CarepathRx Health Systems Solutions, alongside capital expenditures of $1.6 billion (10).
Glossary
- Revenue: Revenue from contracts with customers, net of sales deductions, as the company itself reports it; not total output, gross revenue, GMV or order intake.
- Op. income: The operating line of the income statement; EBIT only as a marked fallback, never pre-tax or ordinary income.
- Op. income (adj.): Adjusted operating income, verbatim and company-defined (non-GAAP), never derived.
- Net income: Net income attributable to the shareholders of the parent, after discontinued operations; not the result including minority interests, not comprehensive income.
- EPS: Diluted earnings per share attributable to the shareholders of the parent; a printed figure always beats a calculated one, calculated values are marked.
- OCF: Cash flow from operating activities as reported; IFRS companies may show interest paid in financing cash flow, so the figure is not always comparable.
- Cash: Cash and cash equivalents, without securities unless the company reports them as part of the position.
- Net Debt: Net debt = financial debt excluding lease liabilities minus cash at the same reporting date; the company's own net position may differ.
- *: derived, the formula is in the hover
- ≈: calculated, approximation
- ~: uncertain; the value stays visible, verdicts do not use it
- °: repaired by a targeted query against the document, or curated with documentary evidence
- EBIT: EBIT as a fallback: the income statement carries no operating line
- basic: basic earnings per share as a fallback when diluted is missing
Sources: quarterly reports, annual reports and investor relations documents
The evidence base for Cigna stock: every document with type and date, every figure in the report leads here by number and to the original by link. NadirAlpha methodology
Older sources (+15)
| # | Document type | Published |
|---|---|---|
| #201 | 10-K annual report | 2019-02-28 |
| #203 | 10-Q quarterly report | 2019-02-28 |
| #204 | 10-K annual report | 2019-02-28 |
| #208 | 10-K annual report | 2019-02-28 |
| #205 | 10-Q quarterly report | 2019-05-02 |
| #202 | 10-Q quarterly report | 2019-08-01 |
| #206 | 10-Q quarterly report | 2019-08-01 |
| #207 | 10-Q quarterly report | 2019-10-31 |
| #212 | 10-K annual report | 2020-02-27 |
| #209 | 10-Q quarterly report | 2020-05-07 |
| #210 | 10-Q quarterly report | 2020-08-06 |
| #211 | 10-Q quarterly report | 2020-11-05 |
| #213 | 10-Q quarterly report | 2021-05-07 |
| #214 | 10-Q quarterly report | 2021-08-05 |
| #215 | 10-Q quarterly report | 2021-11-04 |
Cigna Stock FAQ
Is there a management forecast (guidance) for FY2026?
Yes. Management has issued targets for FY2026, including EPS (non-GAAP). The guidance tracking chapter shows all targets and checks them against the actuals reported later; neutral, with no estimate of our own.
Which additional key figures does Cigna report?
As reported for Q2 2026: Total Pharmacy Customers, Total Medical Customers, Total Customer Relationships, Cigna Healthcare Medical Care Ratio, Dental Customers, Behavioral Care Customers. The chapter Reported KPIs lists every value with its source. Revenue is broken down by Other Operations, Evernorth Health Services - Pharmacy Benefit Services, Evernorth Health Services - Specialty and Care Services, Pharmacy Benefit Services.
Does Cigna pay a dividend?
The filings report on the dividend; most recent entry: dividends paid $2.4 billion (FY2024) (as reported, no assessment of our own). Details with source links are in the report chapters.
Where can I find the official investor relations documents of Cigna?
NadirAlpha links all 45 original filings used (SEC filings) in the sources chapter: quarterly report, earnings release, annual report, each with type, publication date and a direct link; every figure in the report carries a source number.